Frontage Holdings (1521) Stock Overview
Provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 1521 from our risk checks.
1521 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Frontage Holdings Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.05 |
| 52 Week High | HK$1.87 |
| 52 Week Low | HK$0.68 |
| Beta | 0.15 |
| 1 Month Change | 15.38% |
| 3 Month Change | -3.67% |
| 1 Year Change | -9.48% |
| 3 Year Change | -46.97% |
| 5 Year Change | -86.96% |
| Change since IPO | -68.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1521 | HK Life Sciences | HK Market | |
|---|---|---|---|
| 7D | 7.1% | -1.6% | -3.9% |
| 1Y | -9.5% | 15.6% | 3.0% |
Return vs Industry: 1521 underperformed the Hong Kong Life Sciences industry which returned 15.6% over the past year.
Return vs Market: 1521 underperformed the Hong Kong Market which returned 3% over the past year.
Price Volatility
| 1521 volatility | |
|---|---|
| 1521 Average Weekly Movement | 10.3% |
| Life Sciences Industry Average Movement | 7.4% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in HK Market | 16.0% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 1521 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1521's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,523 | John Lin | www.frontagelab.com |
Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies. It offers drug discovery services comprising medicinal chemistry, pharmacology, and efficacy, as well as absorption, distribution, metabolism, and excretion (ADME) screening. The company also provides drug metabolism and pharmacokinetics (DMPK); safety and toxicology; early phase clinical services; and bioequivalence and related services, such as pharmacology, medical writing, and regulatory support.
Frontage Holdings Corporation Fundamentals Summary
| 1521 fundamental statistics | |
|---|---|
| Market cap | HK$2.13b |
| Earnings (TTM) | HK$53.24m |
| Revenue (TTM) | HK$2.01b |
Is 1521 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1521 income statement (TTM) | |
|---|---|
| Revenue | US$256.69m |
| Cost of Revenue | US$187.49m |
| Gross Profit | US$69.20m |
| Other Expenses | US$62.41m |
| Earnings | US$6.79m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0034 |
| Gross Margin | 26.96% |
| Net Profit Margin | 2.65% |
| Debt/Equity Ratio | 22.0% |
How did 1521 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/21 00:12 |
| End of Day Share Price | 2026/06/18 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Frontage Holdings Corporation is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Bo Li | CLSA |
| Yinglong Pan | Goldman Sachs |